Hereditary nonpolyposis colorectal cancer medical therapy
|
Hereditary Nonpolyposis Colorectal Cancer Microchapters |
|
Differentiating Hereditary Nonpolyposis Colorectal Cancer from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hereditary nonpolyposis colorectal cancer medical therapy On the Web |
|
American Roentgen Ray Society Images of Hereditary nonpolyposis colorectal cancer medical therapy |
|
FDA on Hereditary nonpolyposis colorectal cancer medical therapy |
|
CDC on Hereditary nonpolyposis colorectal cancer medical therapy |
|
Hereditary nonpolyposis colorectal cancer medical therapy in the news |
|
Blogs on Hereditary nonpolyposis colorectal cancer medical therapy |
|
Directions to Hospitals Treating Hereditary nonpolyposis colorectal cancer |
|
Risk calculators and risk factors for Hereditary nonpolyposis colorectal cancer medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]Ali Akram, M.B.B.S.[3]
Overview
There is no medical treatment for hereditary nonpolyposis colorectal cancer. However, hereditary nonpolyposis colorectal cancer patients should consider diet optimization and pharmacological prevention.
Medical Therapy
Patients with hereditary nonpolyposis colorectal cancer should consider the following options of medical management:
Diet Optimization
- Patients with high risk of colorectal cancer should consider a low fat diet with limitations concerning red meat.[1][2]
- Dietary approaches should consider the inclusion of high fiber and rich in cellulose foods.
Pharmacological Prevention
The real value of these drugs in cancer prevention in hereditary nonpolyposis colorectal cancer cannot be excluded, but is not definitely proven. Further studies are needed to find the optimal dosage and duration of therapy for these medications.
References
- ↑ W. C. Willett, M. J. Stampfer, G. A. Colditz, B. A. Rosner & F. E. Speizer (1990). "Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women". The New England journal of medicine. 323 (24): 1664–1672. doi:10.1056/NEJM199012133232404. PMID 2172820. Unknown parameter
|month=ignored (help) - ↑ Jozef Kladny & Jan Lubinski (2008). "Lynch syndrome (HNPCC)". Hereditary cancer in clinical practice. 6 (2): 99–102. doi:10.1186/1897-4287-6-2-99. PMID 19804605. Unknown parameter
|month=ignored (help) - ↑ H. T. Lynch & J. Lynch (2000). "Lynch syndrome: genetics, natural history, genetic counseling, and prevention". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18 (21 Suppl): 19S–31S. PMID 11060321. Unknown parameter
|month=ignored (help) - ↑ Matthew B. Yurgelun & Heather Hampel (2018). "Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention". American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting (38): 101–109. doi:10.1200/EDBK_208341. PMID 30231390. Unknown parameter
|month=ignored (help) - ↑ Jozef Kladny & Jan Lubinski (2008). "Lynch syndrome (HNPCC)". Hereditary cancer in clinical practice. 6 (2): 99–102. doi:10.1186/1897-4287-6-2-99. PMID 19804605. Unknown parameter
|month=ignored (help) - ↑ Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S; et al. (2011). "Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial". Lancet. 378 (9809): 2081–7. doi:10.1016/S0140-6736(11)61049-0. PMC 3243929. PMID 22036019.
- ↑ Lu KH, Loose DS, Yates MS, Nogueras-Gonzalez GM, Munsell MF, Chen LM; et al. (2013). "Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome". Cancer Prev Res (Phila). 6 (8): 774–81. doi:10.1158/1940-6207.CAPR-13-0020. PMC 3737517. PMID 23639481.